News

Updated HIV, HCV, HBV blood product screening test approved


 

References

An updated version of a blood screening assay that detects human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV), and hepatitis B virus (HBV) in donated blood has been approved by the Food and Drug Administration, the manufacturer, Roche, recently announced.

In a Jan. 9 press release, the company said that its “cobas TaqScreen MPX Test, v2.0” was approved for use “in the detection and identification” of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma. The test “provides increased sensitivity and is the only FDA approved test to simultaneously detect and identify the most critical viral targets in one simple, ready-to-use assay.,“ according to the statement.

emechcatie@frontlinemedcom.com

Recommended Reading

New drugs are ‘nice’ but many IBD questions remain open for study
MDedge Internal Medicine
Gilead’s hepatitis C drugs to be sold exclusively at CVS
MDedge Internal Medicine
Sample size, patient selection keys to successful small studies
MDedge Internal Medicine
Microbiota organization influences colorectal cancers
MDedge Internal Medicine
Analysis: Push for expanded hepatitis C screening appears premature
MDedge Internal Medicine
Transsplenic TIPS procedure catching on for portal vein thrombosis
MDedge Internal Medicine
FDA approves vagal blocking device for obesity
MDedge Internal Medicine
Stage IV CRC survival rates up, resection rates down
MDedge Internal Medicine
Aetna customers to receive discount on Gilead’s hepatitis C treatment
MDedge Internal Medicine
Vitamin D appears protective in patients with metastatic colorectal cancer
MDedge Internal Medicine